Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's mitapivat headlines the EHA Plenary with breakthrough Phase 3 sickle cell data.

In Part 2 we cover:

4. Novo Nordisk — CagriSema (cagrilintide + semaglutide) for type 2 diabetes (Phase 3)

5. Takeda — Zasocitinib for moderate-to-severe plaque psoriasis (Phase 3)

6. Agios Pharmaceuticals — Mitapivat for sickle cell disease (Phase 3)

Mitapivat is a once-daily pill that flips on an enzyme inside red blood cells so they can make more energy and resist the sickling that causes excruciating pain crises. The Phase 3 RISE UP data, presented at the prestigious EHA 2026 Plenary, showed it both raises hemoglobin and cuts pain crises — a long-overdue option for a disease with very few approved therapies that disproportionately affects Black communities globally.

Catch Part 1 if you missed it. Subscribe at TrialBreaks.com.

#biomedicine #clinicaltrials #science #diabetes #GLP1 #obesity #sicklecell #hematology #psoriasis #dermatology #immunology #raredisease #metabolic